Cara Therapeutics - CARA Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CARA shares.
View CARA analyst ratings or view top-rated stocks.

6 Wall Street research analysts have issued 12 month price objectives for Cara Therapeutics' stock. Their CARA share price forecasts range from $6.00 to $25.00. On average, they anticipate the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 232.7% from the stock's current price.
View analysts price targets for CARA or view top-rated stocks among Wall Street analysts.

Cara Therapeutics' stock was trading at $10.74 on January 1st, 2023. Since then, CARA stock has decreased by 52.4% and is now trading at $5.11.
View the best growth stocks for 2023 here.

Cara Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 5,140,000 shares, a drop of 6.4% from the February 28th total of 5,490,000 shares. Based on an average trading volume of 588,000 shares, the days-to-cover ratio is presently 8.7 days. Currently, 12.2% of the shares of the company are short sold.
View Cara Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our CARA earnings forecast.

Cara Therapeutics, Inc. (NASDAQ:CARA) posted its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.34. The biopharmaceutical company earned $20.27 million during the quarter, compared to the consensus estimate of $15.74 million. Cara Therapeutics had a negative net margin of 204.16% and a negative trailing twelve-month return on equity of 45.46%. During the same quarter last year, the company posted ($0.35) EPS.

ETFs with the largest weight of Cara Therapeutics (NASDAQ:CARA) stock in their portfolio include Amplify Seymour Cannabis ETF (CNBS), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Pharmaceuticals ETF (XPH), Invesco S&P SmallCap Health Care ETF (PSCH), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Pharmaceuticals ETF (IHE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), GW Pharmaceuticals (GWPH), Novavax (NVAX), INSYS Therapeutics (INSY), Fate Therapeutics (FATE) and Incyte (INCY).

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (1.89%), Geode Capital Management LLC (1.60%), Pinnacle Associates Ltd. (1.32%), Pinnacle Associates Ltd. (1.28%), Bank of America Corp DE (1.25%) and Morgan Stanley (0.92%). Insiders that own company stock include Christopher Posner, Derek T Chalmers, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Martin Vogelbaum, Scott Terrillion and Thomas Charles Reilly.
View institutional ownership trends.

Shares of CARA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CARA stock can currently be purchased for approximately $5.11.

Cara Therapeutics (NASDAQ:CARA) has a market capitalization of $275.63 million and generates $41.87 million in revenue each year. The biopharmaceutical company earns $-85,470,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The official website for the company is www.caratherapeutics.com. The biopharmaceutical company can be reached via phone at (203) 406-3700, via email at janhavi.mohite@sternir.com, or via fax at 203-567-1510.